{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:13:11Z","timestamp":1786486391345,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T00:00:00Z","timestamp":1470960000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40262-016-0433-0","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T06:33:04Z","timestamp":1470983584000},"page":"179-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis"],"prefix":"10.1007","volume":"56","author":[{"given":"Raju","family":"Subramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Benjamin","family":"Hock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethlyn J.","family":"Sloey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah F.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogo","family":"Egbuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Greg","family":"Slatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Skiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,12]]},"reference":[{"issue":"2","key":"433_CR1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1517\/14728214.2015.1018177","volume":"20","author":"M Cozzolino","year":"2015","unstructured":"Cozzolino M, Tomlinson J, Walsh L, Bellasi A. Emerging drugs for secondary hyperparathyroidism. Expert Opin Emerg Drugs. 2015;20(2):197\u2013208.","journal-title":"Expert Opin Emerg Drugs."},{"issue":"4","key":"433_CR2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00041552-200307000-00002","volume":"12","author":"LD Quarles","year":"2003","unstructured":"Quarles LD. Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues. Curr Opin Nephrol Hypertens. 2003;12(4):349\u201355.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"433_CR3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/mol.115.098392","volume":"88","author":"ST Alexander","year":"2015","unstructured":"Alexander ST, Hunter T, Walter S, Dong J, Maclean D, Baruch A, et al. Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol. 2015;88(5):853\u201365.","journal-title":"Mol Pharmacol"},{"key":"433_CR4","unstructured":"Cunningham J, The\u00a0Trial\u00a0Steering\u00a0Committee. A long acting intravenous calcimimetic (AMG 416) for secondary hyperparathyroidism (SHPT) in haemodialysed patients [abstract]. 52nd European Renal Association\u2014European Dialysis Transplant Association Congress: London; 28\u201331 May 2015."},{"issue":"8","key":"433_CR5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1124\/dmd.115.068007","volume":"44","author":"R Subramanian","year":"2016","unstructured":"Subramanian R, Zhu X, Kerr SJ, Esmay JD, Louie SW, Edson KZ, et al. Nonclinical pharmacokinetics disposition, and drug-drug interaction potential of a novel D-amino acid peptide agonist of the calcium sensing receptor AMG 416 (etelcalcetide). Drug Metab Dispos. 2016;44(8):1319\u201331.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"433_CR6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","volume":"85","author":"KJ Martin","year":"2014","unstructured":"Martin KJ, Pickthorn K, Huang S, Block GA, Vick A, Mount PF, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. 2014;85(1):191\u20137.","journal-title":"Kidney Int"},{"issue":"10","key":"433_CR7","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/jcph.314","volume":"54","author":"J Shen","year":"2014","unstructured":"Shen J, Xiao J, Pickthorn K, Huang S, Bell G, Vick A, et al. A pharmacokinetic\/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects. J Clin Pharmacol. 2014;54(10):1125\u201333.","journal-title":"J Clin Pharmacol"},{"key":"433_CR8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ndt\/gft417","volume":"29","author":"KJ Martin","year":"2014","unstructured":"Martin KJ, Bell G, Pickthorn K, Huang S, Vick A, Hodsman P, et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant. 2014;29:385\u201392.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"433_CR9","first-page":"24","volume":"1","author":"KZ Edson","year":"2016","unstructured":"Edson KZ, Wu BM, Iyer A, Goodman W, Skiles GL, Subramanian R. Determination of etelcalcetide biotransformation and hemodialysis kinetics to guide the timing of its dosing. KI Rep. 2016;1(1):24\u201333.","journal-title":"KI Rep."},{"issue":"6","key":"433_CR10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/jcph.460","volume":"55","author":"P Chen","year":"2015","unstructured":"Chen P, Melhem M, Xiao J, Kuchimanchi M, Perez Ruixo JJ. Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. J Clin Pharmacol. 2015;55(6):620\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"433_CR11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1185\/03007995.2015.1031731","volume":"31","author":"G Bell","year":"2015","unstructured":"Bell G, Huang S, Martin KJ, Block GA. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin. 2015;31(5):943\u201352.","journal-title":"Curr Med Res Opin"},{"issue":"15","key":"433_CR12","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516\u201325.","journal-title":"N Engl J Med"},{"key":"433_CR13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.freeradbiomed.2013.05.050","volume":"65","author":"L Turell","year":"2013","unstructured":"Turell L, Radi R, Alvarez B. The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radic Biol Med. 2013;65:244\u201353.","journal-title":"Free Radic Biol Med"},{"key":"433_CR14","unstructured":"Common Terminology Criteria for Adverse Events version 4.0. Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf . Accessed 11 Mar 2016."},{"issue":"1","key":"433_CR15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/03602530600952172","volume":"39","author":"SJ Roffey","year":"2007","unstructured":"Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 2007;39(1):17\u201343.","journal-title":"Drug Metab Rev"},{"issue":"6","key":"433_CR16","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ki.1984.114","volume":"25","author":"KL Duchin","year":"1984","unstructured":"Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ. Elimination kinetics of captopril in patients with renal failure. Kidney Int. 1984;25(6):942\u20137.","journal-title":"Kidney Int"},{"key":"433_CR17","unstructured":"KYNAMRO\u00ae (mipomersen sodium) injection. Cambridge: Genzyme Corporation; 2015."},{"key":"433_CR18","volume-title":"Lyxumia (lixisenatide). Summary of product characteristics","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. Lyxumia (lixisenatide). Summary of product characteristics. London: Sanofi-Aventis; 2015."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0433-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0433-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0433-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0433-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:35:17Z","timestamp":1498322117000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0433-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,12]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0433-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,12]]}}}